- Home
- BIIB
BIIB
Biogen Inc.
as 11-21-2025 3:37pm EST
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 24.2B | IPO Year: | 1991 |
| Target Price: | $176.48 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 10.97 | EPS Growth: | -0.78 |
| 52 Week Low/High: | $110.03 - $176.02 | Next Earning Date: | 10-30-2025 |
| Revenue: | $10,065,900,000 | Revenue Growth: | 4.77% |
| Revenue Growth (this year): | 2.97% | Revenue Growth (next year): | -5.02% |
Stock Insider Trading Activity of Biogen Inc. (BIIB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Singhal Priya | BIIB | Head of Development | Sep 2 '25 | Sell | $133.55 | 517 | $69,045.35 | 5,772.143 |
Latest Biogen Inc. News
BIIB Breaking Stock News: Dive into BIIB Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Piper Sandler Adjusts Price Target on Biogen to $157 From $118, Maintains Neutral Rating
GlobeNewswire
3 days ago
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
Barrons.com
3 days ago
Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.
Simply Wall St.
4 days ago
A Look at Biogen (BIIB) Valuation Following New Dravet Syndrome Study Results
GlobeNewswire
4 days ago
Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion
Barchart
5 days ago
Biogen Stock: Is Wall Street Bullish or Bearish?
MT Newswires
6 days ago
Biogen Says EU Committee Recommends Approval of High Dose Nusinersen Regimen
GlobeNewswire
6 days ago
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Compare BIIB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIIB Biogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.